# The Effects of Sevelamer Carbonate on Diabetic Nephropathy

Study · id `cardio:ct-nct01493050` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01493050](<https://clinicaltrials.gov/study/NCT01493050>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01493050

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 117 participants.

## Technical summary

Registry record NCT01493050. Randomized; quadruple masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2013-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 117 participants (enrolled count; ClinicalTrials.gov record NCT01493050, source copy `cardio:ctgov-nct01493050-2014-04-09`, retrieved 2026-10-26)
- Start date: 2012-02 (registry gives no type) (ClinicalTrials.gov record NCT01493050, source copy `cardio:ctgov-nct01493050-2014-04-09`, retrieved 2026-10-26)
- Primary completion: 2013-12 (actual) (ClinicalTrials.gov record NCT01493050, source copy `cardio:ctgov-nct01493050-2014-04-09`, retrieved 2026-10-26)
- Completion: 2013-12 (actual) (ClinicalTrials.gov record NCT01493050, source copy `cardio:ctgov-nct01493050-2014-04-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01493050, source copy `cardio:ctgov-nct01493050-2014-04-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01493050-2014-04-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effects of Sevelamer Carbonate on Diabetic Nephropathy
- Condition: Diabetic Nephropathy
- Intervention (Drug): Sevelamer Carbonate
- Intervention (Drug): calcium carbonate
- Lead sponsor: Gary Striker
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 53d077808d5b4f8d3352e3b3cd51d1ea98d40304433193ecfd3bffabb6eef588
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
